What Dianthus Therapeutics, Inc. /DE/'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 18 | 71 |
| Total trades | 33 | 117 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 169,944 | 906,355 |
| Disposed | 169,944 | 826,063 |
| Net activity | +0 | +80,292 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Savitz Ryan | EVP, CFO & CBO | Nov 12 | Open-market sale · S | −17,724 | $90.56 | −$1.61M | 0 |
| Savitz Ryan | EVP, CFO & CBO | Nov 12 | Exercise / conversion · M | +16,385 | $22.07 | +$362K | 17,724 |
| Savitz Ryan | EVP, CFO & CBO | Nov 12 | Exercise / conversion · M | +1,339 | $21.77 | +$29.2K | 1,339 |
| Savitz Ryan | EVP, CFO & CBO | Nov 11 | Open-market sale · S | −3,044 | $90.03 | −$274K | 0 |
| Savitz Ryan | EVP, CFO & CBO | Nov 11 | Exercise / conversion · M | +1,300 | $22.07 | +$28.7K | 3,044 |
| Savitz Ryan | EVP, CFO & CBO | Nov 11 | Exercise / conversion · M | +1,744 | $21.77 | +$38K | 1,744 |
| Savitz Ryan | EVP, CFO & CBO | Nov 10 | Open-market sale · S | −2,561 | $90.14 | −$231K | 0 |
| Savitz Ryan | EVP, CFO & CBO | Nov 10 | Exercise / conversion · M | +1,260 | $22.07 | +$27.8K | 2,561 |
| Savitz Ryan | EVP, CFO & CBO | Nov 10 | Exercise / conversion · M | +1,301 | $21.77 | +$28.3K | 1,301 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Open-market sale · S | −2,064 | $91.59 | −$189K | 0 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Open-market sale · S | −58,396 | $90.90 | −$5.31M | 2,064 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Open-market sale · S | −37,517 | $90.12 | −$3.38M | 60,460 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Open-market sale · S | −1,736 | $88.84 | −$154K | 97,977 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Open-market sale · S | −700 | $86.70 | −$60.7K | 99,713 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Open-market sale · S | −300 | $85.16 | −$25.5K | 100,413 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Exercise / conversion · M | +10,399 | $8.44 | +$87.8K | 100,713 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Exercise / conversion · M | +40,430 | $22.07 | +$892K | 90,314 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Exercise / conversion · M | +20,608 | $21.77 | +$449K | 49,884 |
| Savitz Ryan | EVP, CFO & CBO | Nov 09 | Exercise / conversion · M | +29,276 | $17.88 | +$523K | 29,276 |
| Carr Edward | CHIEF ACCOUNTING OFFICER | Sep 17 | Open-market sale · S | −700 | $104.39 | −$73.1K | 0 |
Loading...